REGENERATION AND TRANSPLANTATIONSalidroside promotes peripheral nerve regeneration following crush injury to the sciatic nerve in ratsSheng, Qing-Songa*; Wang, Zhi-Junc*; Zhang, Jund; Zhang, Yong-GuangbAuthor Information aDepartment of Obstetrics and Gynecology bDepartment of Orthopaedics, Fuzhou General Hospital, Fuzhou cDepartment of Radiology, General Hospital of Ningxia Medical University, Yinchuan dDepartment of Pharmacology, Fourth Military Medical University, Xi’an, China *Qing-Song Sheng and Zhi-Jun Wang contributed equally to the writing of this article. Correspondence to Yong-Guang Zhang, Institution of Orthopaedics, Fuzhou General Hospital, 156 West Ring Road, Fuzhou 350025, China Tel/fax: +86 0591 22859844; e-mail: firstname.lastname@example.org Received December 15, 2012 Accepted December 30, 2012 NeuroReport: March 27th, 2013 - Volume 24 - Issue 5 - p 217-223 doi: 10.1097/WNR.0b013e32835eb867 Buy SDC Metrics Abstract Salidroside (SDS), a phenylpropanoid glycoside isolated from Rhodiola rosea L., has been reported to be neuroprotective in vitro, which raises the possibility of using SDS as a neuroprotective agent after nerve injuries. In the present study, the possibly beneficial effect of SDS on promoting nerve regeneration after sciatic nerve crush injury in rats was investigated. Rats with sciatic nerve crush injury were administered intraperitoneally daily with 5 or 10 mg/kg body weight of SDS for 4 weeks. Rats that received mecobalamin or saline were considered as a positive or a negative control, respectively. Morphometric analysis of regenerated nerves and Fluoro-Gold retrograde tracing was used to evaluate axonal regeneration, whereas walking track analysis, electrophysiological assessment, and histological appearance of target muscles were carried out to evaluate the recovery of motor function. The results showed that SDS achieved functionally successful nerve regeneration in the rat sciatic nerve crush injury model, indicating that SDS holds potential as a neuroprotective agent for peripheral nerve therapies. © 2013 Lippincott Williams & Wilkins, Inc.